Bladder cancer is staged from 0 to IV based on how deeply the tumor has grown into the bladder wall and whether it has spread to nearby tissues, lymph nodes, or distant organs. The earliest stages are confined to the bladder’s inner lining, while later stages involve the muscle wall or areas beyond the bladder. Understanding where a tumor falls on this spectrum shapes virtually every treatment decision.
How Bladder Cancer Is Staged
Staging starts with a procedure called transurethral resection, where a surgeon inserts a thin instrument through the urethra and removes tumor tissue along with some of the surrounding bladder muscle. A pathologist then examines the sample under a microscope to determine how far cancer cells have penetrated the bladder wall. This distinction between layers is the single most important factor in staging.
Imaging scans, typically CT or MRI, help determine whether cancer has spread beyond the bladder to lymph nodes or other organs. Together, the tissue sample and imaging results produce a clinical stage that guides treatment.
Stage 0: Cancer on the Surface Only
Stage 0 means cancer cells are found in the tissue lining the inside of the bladder but have not invaded the bladder wall at all. It divides into two subtypes based on the growth pattern.
Stage 0a (noninvasive papillary carcinoma) appears as long, thin, finger-like growths that extend into the open space where urine collects. These are the most common early bladder tumors. Stage 0is (carcinoma in situ) is a flat tumor that stays along the bladder lining. Despite being flat and surface-level, carcinoma in situ is considered high-grade, meaning its cells look more abnormal and carry a higher risk of becoming invasive over time.
Treatment for both subtypes typically begins with surgical removal of the tumor through the urethra. Because stage 0 tumors frequently come back, most people also receive medication delivered directly into the bladder after surgery. For higher-risk tumors, this treatment may continue for up to three years. If carcinoma in situ keeps returning despite treatment, partial or complete removal of the bladder becomes an option.
Stage I: Into the Lining, Not the Muscle
At stage I, cancer has grown through the bladder’s innermost lining into the connective tissue beneath it, but it has not reached the muscle layer of the bladder wall. This is still classified as non-muscle-invasive bladder cancer, which is a critical distinction because it keeps more treatment options on the table.
Treatment follows a similar path to stage 0: surgical removal through the urethra followed by medication placed directly in the bladder. The most commonly used bladder treatment is a form of immunotherapy that uses a weakened strain of bacteria to trigger the immune system to attack remaining cancer cells.
Recurrence is a real concern at this stage. Among patients with high-grade stage I tumors treated with ongoing bladder immunotherapy, roughly 11% see their cancer progress to a deeper stage within one year, and about 20% within five years. The number of tumors present and a patient’s history of prior recurrences are the strongest predictors of whether the cancer will come back or advance.
Stage II: Cancer Reaches the Muscle
Stage II marks a significant turning point. Cancer has spread through the connective tissue into the muscle layers of the bladder wall. Once a tumor is muscle-invasive, the treatment approach changes substantially.
The two main options for stage II are removing the bladder entirely (radical cystectomy) or a combination of radiation therapy and chemotherapy aimed at preserving the bladder. Radical cystectomy also removes surrounding tissues. In men, this typically includes the prostate and seminal vesicles. In women, it may include the uterus and part of the vaginal wall. When the bladder is removed, surgeons create a new pathway for urine to leave the body, either through an external bag or by constructing an internal reservoir from a segment of intestine.
In some cases, only part of the bladder is removed, though this is less common. Chemotherapy before surgery (given through a vein, not into the bladder) is standard for patients healthy enough to tolerate it, as it improves outcomes by targeting any cancer cells that may have spread microscopically.
Stage III: Through the Bladder Wall
In stage III, cancer has grown all the way through the bladder muscle and wall into the layer of fat surrounding the bladder. It may have also spread to nearby reproductive organs, such as the prostate or seminal vesicles in men, or the uterus or vagina in women. Stage IIIA specifically means cancer has reached these surrounding structures but has not yet spread to lymph nodes, while stage IIIB involves nearby lymph node involvement.
Treatment options for stage III mirror those for stage II but tend to be more aggressive. Radical cystectomy with chemotherapy before or after surgery is the most common approach. The combination of radiation and chemotherapy remains an alternative for patients who are not candidates for major surgery or who want to preserve their bladder.
Stage IV: Advanced or Metastatic Disease
Stage IV is divided into two subcategories. Stage IVA means cancer has spread to the abdominal or pelvic wall, or to lymph nodes further from the bladder. Stage IVB means cancer has metastasized to distant organs, most commonly the lungs, liver, or bones.
Treatment at this stage focuses on controlling the disease and extending survival. Options include combinations of immunotherapy drugs (which help the immune system recognize and attack cancer), chemotherapy, and targeted therapies. Newer treatment combinations pairing immunotherapy with targeted drugs have expanded options considerably for stage IV patients. For people whose cancer is locally advanced but hasn’t spread to distant sites, chemotherapy-based regimens remain a core approach, sometimes followed by maintenance immunotherapy.
Grade vs. Stage
Stage and grade are related but measure different things. Stage describes how far cancer has physically spread. Grade describes how abnormal the cancer cells look under a microscope and how quickly they’re likely to grow. Bladder cancer is graded as either low-grade or high-grade.
Low-grade tumors have cells that still resemble normal bladder tissue and tend to grow slowly. High-grade tumors look more disorganized and are more likely to invade deeper layers or spread. A stage 0 tumor that is high-grade (like carcinoma in situ) can be more dangerous than its early stage might suggest, which is why grade and stage together determine the treatment plan.
Survival Rates by Stage
Five-year relative survival rates, based on data from 2016 to 2022, give a broad picture of outcomes. For localized bladder cancer (confined to the bladder, covering stages 0 through II), the five-year survival rate is 73%. About 34% of bladder cancers are diagnosed at this localized stage.
When cancer has spread to regional lymph nodes, the five-year survival drops to about 42%. Only 7% of cases are diagnosed at this regional stage. For distant metastatic disease, the five-year survival rate is roughly 10%, and about 6% of patients are diagnosed at this point.
These numbers are population averages and don’t account for individual factors like age, overall health, tumor grade, or how well a person responds to treatment. They also reflect outcomes for patients diagnosed several years ago, before some of the newer immunotherapy combinations became widely available.